Drug Combination Details
| General Information of the Combination (ID: C97303) | |||||
|---|---|---|---|---|---|
| Name | Phytosphingosine NP Info | + | Gamma-ray irradiation Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | AIF nuclear translocation | ||||
| Induction | Bax mitochondrial relocalization | |||||
| Induction | ROS accumulation | |||||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation. | |||||
